Toronto · Independent Shariah screening · Updated daily
Market news · Researched from public market reporting · Content-only (no affiliate programs)

Novo Nordisk Beat on the Wegovy Pill and Raised Guidance — but Would Not Call 2027: the Halal Investor's Read (2026)

Wednesday was the best day Novo Nordisk has had in months, and the most honest sentence of the day was the one management refused to say. The Danish drugmaker reported a third quarter that beat expectations on the lines that matter: adjusted sales of 79.20 billion Danish kroner against 73.22 billion expected, adjusted operating profit of 31.72 billion kroner, up 27 percent at constant exchange rates, against 28.39 billion expected, and adjusted earnings per share of 5.79 kroner against 4.80 expected. The shares rose as much as 6.6 percent in early trade in Copenhagen and were up 4.2 percent at 1318 GMT, headed for their biggest daily gain since 19 June, according to Reuters. The company raised its full-year 2026 outlook for the third time this year. And then chief executive Mike Doustdar declined to issue guidance for 2027 at all, pushing that reckoning to the full-year results in February 2027. The reason is not hard to find: from 1 January 2027, Novo will cut the United States list prices of Wegovy by about 50 percent and Ozempic by about 35 percent, to 675 dollars a month for each. This article separates the beat from the price cut, explains why a pill is now carrying a company that used to be carried by injections, and then runs the whole thing through the Shariah screen — because the screen is where this story is calmest, and that calm is itself the point.

Updated November 2026 · Reviewed by the Canadian Halal Investor team

What actually happened on Wednesday

Novo Nordisk reported third-quarter 2026 results on Wednesday 4 November, and the market's reaction was immediate and unusually large for a company of this size. The Copenhagen-listed shares rose as much as 6.6 percent in early trade and were up 4.2 percent at 1318 GMT, headed for their biggest daily gain since 19 June, according to Reuters. United States-listed shares climbed more than 5 percent in premarket trading after the announcement. That is a strong reaction for a beat, and it is worth asking why it was so strong — because the headline numbers, read alone, do not quite explain it. Adjusted sales rose only 4 percent at constant exchange rates, net profit fell 16 percent in Danish kroner, and adjusted earnings per share fell 12 percent from a year earlier. A company whose profit fell is not usually rewarded with its best day in months. The explanation lies in what the market had feared, and in which part of the business did the growing.

The fear, first, was the trajectory. Novo is, in Reuters' words, clawing back into the obesity drug race after sliding sales and shares in recent years, and the shares were down about 13 percent for the year before Wednesday's report. At the start of 2026 the company itself expected adjusted sales and operating profit to decline by 5 to 13 percent for the year. In August it narrowed that to a decline of 0 to 6 percent. On Wednesday it raised the range again, to between a 2 percent decline and 2 percent growth for both adjusted sales and adjusted operating profit at constant exchange rates. That is the third guidance raise of the year, and the new range sits above the old one at both ends: the floor moved from a 6 percent decline to a 2 percent decline, and the ceiling moved from flat to 2 percent growth. Jefferies, which reaffirmed its Hold rating and a 275 kroner price target, noted that consensus estimates could rise because the improved outlook sits above prior expectations. The market was not rewarding a single quarter. It was rewarding a company whose own forecast for the year has moved from a double-digit decline to roughly flat in the space of ten months.

There was also a leadership subplot on the same day, and it belongs in the same paragraph because it shapes how the next year will be managed. Novo appointed Luigi La Corte, currently finance chief at Galderma, as executive vice president and chief financial officer. Karsten Munk Knudsen, the outgoing finance chief, will leave the company at year-end after 27 years. A chief financial officer change on results day is not, by itself, a signal in either direction — but it does mean the person who will have to explain the 2027 numbers in February is new to the job, which makes the deferred guidance decision easier to understand. The chief executive declined to call 2027; the incoming finance chief will be the one who has to own the call when it comes. That sequencing is worth noting, not because it changes any number, but because it tells you the company knows the next forecast will be the hard one.

The broader market context also matters, because Wednesday was a strong day for stocks generally, and a rising market flatters every beat. The S&P 500 rose more than 1.5 percent and the Dow more than 2 percent in the day's reporting, as investors digested a heavy earnings slate and the midterm election result that handed control of Congress to the Democrats. Tuesday night's AMD and Arista beats were still lifting chip stocks. Against that tape, a 4 to 6 percent rise in Novo is not purely a Novo story — but the scale of the move, the biggest since June, says the market read something specific in this report, and the specific thing was the pill. The rest of this article is about why a single product form — a daily tablet instead of a weekly injection — is doing so much work in this company's numbers, and why the same pill is also the reason management would not call 2027.

The quarter: a beat built on the pill

Start with the numbers as reported, because the gap between the adjusted figures and the reported figures is the first thing a careful reader should see. Adjusted sales for the third quarter were 79.20 billion Danish kroner, up 4 percent at constant exchange rates and 6 percent in reported terms, against a Reuters consensus of 73.22 billion. Adjusted operating profit was 31.72 billion kroner, up 27 percent at constant exchange rates, against 28.39 billion expected — a beat of roughly 12 percent on the profit line, larger than the roughly 8 percent beat on the sales line. Adjusted earnings per share came in at 5.79 kroner, down 12 percent from a year earlier, but comfortably above the 4.80 analysts had projected. On the adjusted measures, which exclude major impairments and one-off items, this was a clear beat on every line.

The reported figures tell a different story, and the difference is not a footnote. Reported operating profit fell 9 percent at constant exchange rates to 23.01 billion kroner, weighed down by 8.7 billion kroner in non-cash impairment charges. Net profit fell 16 percent in Danish kroner to 16.74 billion. The gap between the adjusted operating profit of 31.72 billion and the reported 23.01 billion is almost entirely those impairments, and the question for a reader is which number to trust. The honest answer is that both are real, and they measure different things. The adjusted figure tells you how the underlying business performed in the quarter — volumes, prices, and costs. The reported figure tells you what the company is worth after writing down assets it no longer expects to recover value from. A 27 percent rise in adjusted operating profit on 4 percent sales growth is a margin story: costs were held, the comparison base was favourable after transformation costs in the prior year, and the mix shifted toward higher-margin products. A 9 percent fall in reported operating profit is a balance-sheet story: something the company built or bought is now worth less than it paid for. Neither cancels the other, and an investor who only reads the adjusted line is missing the write-down, just as an investor who only reads the reported line is missing the operating improvement.

The segment detail shows where the growth actually came from, and it is narrow. Obesity care sales rose 22 percent at constant exchange rates to 26.15 billion kroner, driven by strong volume growth across geographies and the accelerated rollout of the Wegovy franchise. Diabetes care, the larger and older business, went the other way: total diabetes sales fell 5 percent at constant exchange rates, with Ozempic down 5 percent. United States revenue nevertheless rose 1 percent, alongside 8 percent international growth, and international GLP-1 sales grew 8 percent at constant exchange rates. Total patient reach rose to 48 million people across diabetes and obesity care, up 2 million from a year earlier. Read together, those lines describe a company whose growth engine has fully switched over: the obesity business is now doing the growing, the diabetes business is shrinking on price pressure, and the international business is growing faster than the American one. That is the shape of the quarter in one sentence, and it is also the shape of the risk, because the obesity business is the one facing the January price cut.

Cash is the third leg of the quarter, and it moved in the company's favour. Full-year free cash flow guidance was raised to 60 to 70 billion kroner from 45 to 55 billion, while planned capital expenditure for the year was cut to 50 billion kroner from 55 billion. Free cash flow exceeded 28 billion kroner in the quarter itself. A company that raises its cash guidance by roughly a third while cutting its spending plan is a company whose cash generation is improving faster than its sales — which is consistent with the margin story in the adjusted profit line. The company also confirmed it is pressing on with its share buyback programme, reporting further weekly repurchases on the Tuesday before results. For a halal investor, the cash picture matters for a specific reason that has nothing to do with the share price: buybacks and dividends are the mechanisms by which a passing company's returns reach shareholders, and Novo is a dividend payer whose distributions would need purification only on the small non-compliant income share, as the purification guide explains. The quarter's cash strength does not change the screen, but it does change the practical question of what a holder actually receives — and the answer this quarter is more cash, sooner, than the company itself expected in August.

The Wegovy pill is now the story

The single most important number in the quarter is not the sales total or the profit total. It is 5.39 billion kroner: the third-quarter revenue of the Wegovy pill. Launched in the United States on 5 January 2026, the pill brought in 5.39 billion kroner in the quarter, up 53 percent on the second quarter and ahead of the 4.62 billion consensus estimate. Of that, 4.18 billion kroner came from the United States. The pill now holds about 80 percent of new-to-brand prescriptions in the United States, and the Wegovy franchise as a whole accounts for more than half of new patient starts among branded obesity drugs. According to a BioSpace report published on results day, 80 percent of patients who started on the Wegovy pill had previously been untreated — which means the pill is not mostly converting existing injection patients. It is bringing in people who were not taking a GLP-1 drug at all.

That last point is the one that explains the market's excitement, and it is worth slowing down for. The injectable version of Wegovy is, by the company's own numbers, in decline in the United States: sales of injectable Wegovy fell 13 percent at constant exchange rates in the quarter. But combined United States Wegovy revenue rose 21 percent once the pill is included. The pill is not a better version of the same business. It is a different market — people who would not inject themselves weekly, or who could not get the injection, or who simply prefer a daily tablet — and it is expanding the treated population rather than fighting over the existing one. Sequential volume for the pill grew 20 percent in the quarter versus the second quarter in the United States, significantly influenced by the Medicare Bridge programme, through which roughly 60,000 weekly prescriptions flowed, according to reporting on the results. That detail matters because it says a meaningful slice of the volume gain came from a single access channel rather than from broad-based demand, and a single channel can narrow as quickly as it widened. The pill's growth is real, but it is not yet proven to be broad.

The rollout is accelerating, and the company is now moving faster than it planned. Novo said high manufacturing output and faster approvals from health authorities had allowed it to speed up the pill's rollout, and it now plans to launch the pill in more than 20 countries by mid-2027, compared with the end-of-2027 target given at its capital markets day in September. It is also preparing to launch CagriSema in the United States early in 2027, subject to regulatory approval, and expects to sell the Wegovy pill in more than 20 markets next year. The CagriSema data point deserves a sentence of its own: in the REIMAGINE 5 trial, CagriSema produced 12.4 percent weight loss, superior to the 9.1 percent demonstrated by the five milligram dose of tirzepatide, Eli Lilly's drug. That is a head-to-head number against the rival's product, and it is the first time in this race that Novo has had a clean comparative win to point to. It does not change the 2026 numbers, and CagriSema is not yet approved, but it changes the shape of the 2027 pipeline — which is precisely the year management declined to forecast.

There is a discipline point here for anyone reading this quarter as a turnaround story. The pill's success is a volume story, and volume at lower prices is a different business from volume at higher prices. The pill is reaching new patients, which is genuinely good, but those patients are arriving through access programmes and at prices that are about to fall sharply. A 53 percent sequential jump in pill revenue is the kind of number that makes a quarter look like a breakthrough, and it is also the kind of number that can be mostly a launch ramp — the first quarters of a new product form, when every new prescription is additive and the comparison base is zero. The honest reading is that the pill has proven it can find patients the injection could not reach, and has not yet proven what those patients are worth over a full year at the prices that will apply from January. That is not a criticism of the quarter. It is the reason the next section exists.

The January price cut: the number that matters for 2027

From 1 January 2027, Novo Nordisk will lower its United States list prices, with Ozempic expected to see an annual decline of 10 to 15 percent and Wegovy cut by about 50 percent, and Ozempic by about 35 percent, both to 675 dollars a month. Read that sentence twice, because it is the most important sentence in this article for anyone thinking about 2027, and it is also the sentence that explains why the chief executive would not give 2027 guidance. A company that cuts the price of its flagship product in half is not making a small adjustment. It is repricing its entire American obesity business, and it is doing so in the same year that its new pill is supposed to carry the growth. The company expects the cuts to weigh on cash flow next year, and Reuters reports that Novo's own annual guidance assumes international growth alongside a decline in the United States — the company's planning does not presuppose a broad upswing across every market.

The price erosion is already visible in the third quarter, before the list-price cuts take effect. Wegovy price erosion was 30 to 35 percent in the United States during the third quarter, reflecting investments in market access and volume-based pricing, and Ozempic price erosion of 10 to 15 percent annually is expected in the United States, driven by payer pressure and net pricing dynamics in the type 2 diabetes category. In other words, the January cuts are not a sudden break from a stable pricing regime. They are the formalisation of a trend that is already running through the numbers: Novo is paying more, in discounts and access programmes, for each patient it adds. The pill's 80 percent share of new-to-brand prescriptions and the 60,000 weekly prescriptions flowing through the Medicare Bridge programme are part of the same picture — volume bought with price. The question for 2027 is not whether the volume will keep growing. It is whether the volume can grow fast enough, at 675 dollars a month, to offset a 50 percent price cut on the product that generates it.

This is where the deferred guidance decision becomes the most informative part of the quarter. A management team that raises its 2026 outlook for the third time in a year, and then declines to give any 2027 outlook at all, is telling you something specific: the 2026 numbers are knowable, and the 2027 numbers are not, because the price cut changes the arithmetic in a way that cannot be modelled from the 2026 run rate. The company said the 2027 forecast will come alongside the full-year figures in February 2027, which is when it must finally connect the dots between more patients, lower prices, and expected financial performance. Until then, any analyst forecast for 2027 is a guess about the elasticity of demand for a weight-loss pill at half the price — a number that has no precedent in this market, because no GLP-1 drug has ever been sold at this scale at this price. The disciplined response is to treat the deferred guidance as information, not as an absence of information: it is management saying, in the plainest way available, that the range of plausible 2027 outcomes is too wide to publish.

For a halal investor, the price cut has a second, quieter implication that belongs in this section rather than the screen section. A price cut of this size compresses margins, and compressed margins change the ratios the screen measures — but only slowly, and only through the denominator. The screen's debt ratio is debt divided by market capitalisation, and the non-compliant income ratio is interest income divided by revenue. A price cut that reduces revenue, without changing debt or interest income, pushes both ratios upward, toward their ceilings. Novo's ratios have a wide margin today — debt at 12.0 percent against a roughly 33 percent ceiling, non-compliant income at 0.41 percent against a 5 percent ceiling — so a single year of price pressure does not threaten the pass. But the direction of travel matters, and it is worth stating plainly: the screen is a snapshot, not a guarantee, and a company whose revenue is shrinking while its debt is flat will screen worse next year than it screens today. That is a reason to recheck the ratios at the next screening refresh, not a reason to change the verdict today.

Novo versus Lilly: the race the market is really pricing

No reading of Novo's quarter is complete without the rival's quarter, because the market is not pricing Novo in isolation. It is pricing a two-company race, and the other company has been winning it. Eli Lilly reported its third quarter on 29 October, a week before Novo, and the numbers were of a different order: revenue up 39 percent to 24.4 billion dollars, Mounjaro up 65 percent to 10.72 billion dollars, Zepbound up 49 percent to 5.35 billion dollars, and full-year guidance raised. Lilly surged on that print, and the contrast with Novo's quarter is stark: Lilly's revenue grew 39 percent while Novo's grew 4 percent, and Lilly's growth came from its core products while Novo's came from a new product form offsetting declines in its established ones. Novo pioneered GLP-1 weight-loss drugs, but Lilly caught up and overtook it in the United States, its biggest market, according to CNBC's reporting on the quarter. Wednesday's beat does not reverse that. It narrows the gap in the story, not in the numbers.

The race has a specific shape that matters for how to read both companies. Lilly's advantage is in the injectable market, where its drugs have taken share from Novo's injections — injectable Wegovy fell 13 percent in the United States in the quarter, and Ozempic fell 5 percent. Novo's answer is not to win the injection race back. It is to change the race: the pill reaches patients the injection does not, and the CagriSema data gives Novo a combination product that, on trial results, beats Lilly's tirzepatide on weight loss. That is a credible strategy, and Wednesday's numbers show it is working at the volume level. But it is also a strategy that concedes the current market while betting on the next one, and the next market — oral GLP-1 drugs at 675 dollars a month — is one where Lilly is also developing products. The pill's 80 percent share of new-to-brand prescriptions in the United States is a strong position in a new category, but a new category with one dominant product is a category a rival can enter, and Lilly has the resources and the pipeline to do so.

There is also a valuation point that frames the race, and it is worth stating because it explains why Novo's shares moved so much on a modest sales beat. At the 3 November Copenhagen closing price of 270.15 kroner, Novo traded at about 11.5 times estimated 2026 earnings, according to independent analysis of the quarter — a low multiple for a company that was, not long ago, Europe's most valuable. Lilly, by contrast, trades at a multiple several times higher, because the market expects its growth to continue. The gap between those multiples is the market's judgement on the two companies' futures, and Wednesday's beat narrowed it slightly without closing it. A halal investor should read that gap the same way the screen reads a ratio: as a fact about expectations, not as a verdict on either company. A low multiple is not a bargain by itself, any more than a high multiple is a bubble by itself. It is the price of the market's belief about what happens next, and the belief about Novo is that the pill and the price cut will roughly cancel each other out — which is, notably, the same judgement the company's own deferred guidance implies.

One more contrast belongs here, because it is the contrast this site's readers will actually use. Both Novo and Lilly pass this site's Shariah screen — Lilly was covered in the 29 October article, where it passed with debt at 5.0 percent and non-compliant income at about 0 percent — which means the race between them is, for a halal investor, a choice between two passing companies rather than a choice between a pass and a fail. That is a genuinely useful position to be in, and it is rarer than it looks: in the same earnings season, CVS fell 12.6 percent on a beat while still failing the screen on debt, and Palantir beat and fell while still failing on non-compliant income. A halal investor choosing between Novo and Lilly is choosing between two companies that have both cleared the gates, on different strengths — Lilly on growth and Novo on a lower valuation and a wider screen margin — and the framework for that choice is the subject of the next sections, not the headline of this one.

What the Shariah screen says: still a pass, by a wide margin

Now the part of the story that did not move, and the part that should anchor the whole article. Novo Nordisk still passes this site's Shariah screen, as of the October 2026 screening, and nothing in Wednesday's results changes that result. The screen works in gates, and Novo passes all three of them — which is the opposite of the CVS story from the same week, and the contrast is the point. The first gate is business activity: is the company's core business permissible? For Novo, that gate passes cleanly. The business is prescription pharmaceuticals — diabetes and obesity care at about 94 percent of revenue, covering Ozempic, Wegovy, Rybelsus and insulins, and rare disease at about 6 percent, covering haemophilia, growth disorders and hormone replacement — sold in roughly 170 countries, with fiscal 2025 sales of 309,064 million kroner. The filings disclose no alcohol, tobacco, gambling, weapons, pork, or interest-based lending businesses. There is no business-activity nuance to flag, no segment to argue about, and no disagreement to report on the first gate. That is worth stating plainly, because it is not true of every healthcare name: the same week's CVS article had to carry an explicit insurance nuance, and Novo carries none.

The second gate is debt, and it passes by a wide margin. Per Novo's own fiscal 2025 net-debt reconciliation, total interest-bearing debt is borrowings of 130,958 million kroner — non-current borrowings of 118,941 million plus current borrowings of 12,017 million — against a market capitalisation of about 171 billion dollars at 2 October 2026. That is a debt ratio of about 12.0 percent, against a ceiling of roughly 33 percent. Cash at bank of 26,464 million kroner plus marketable securities of 498 million kroner is about 2.5 percent of market capitalisation. Lease liabilities of 8,572 million kroner are reported and added back separately, so they are not in the debt figure — a detail the screener page states explicitly, because the treatment of leases is one of the places where different screens can disagree, and this site's rule is to show its working. The debt gate is not close. It would take a very large increase in borrowing, or a very large fall in market value, to bring 12.0 percent near 33 percent, and neither is visible in Wednesday's report.

The third gate is non-compliant income, and it passes by the widest margin of the three. Novo's Annual Report 2025 discloses interest income of 1,269 million kroner as a separately reported financial-items line, against revenue of 309,064 million kroner — about 0.41 percent of revenue, well below the 5 percent ceiling. Reported financial items, net, for fiscal 2025 were a gain of 2,882 million kroner, driven by currency hedging gains and partly offset by interest expenses on the debt that funded the Catalent transaction. The gate is assessed on the disclosed interest-income line, which is the figure the screen measures, and it passes comfortably. Independent screens agree with the direction of the result: Zoya rates Novo Shariah-compliant and Musaffa classifies it halal, both as of October 2026, and no ShariaPortfolio rating for Novo was found — reported as absent, not invented. There is no third-party disagreement to report on this name, which is itself a useful fact: the screens that cover Novo agree, and the one that does not cover it is named rather than assumed.

Two further checks complete the picture, because the site's screening does not stop at the three financial gates. The BDS screen finds no listing: Novo does not appear on the BDS movement's published boycott, divestment, or pressure lists, as checked in October 2026 — reported as informational context, not as a change to the screen result, and not as a ruling. The moral screen, which checks documented business ties to the Israeli and United States militaries and to weapons manufacturing, surfaced no findings for Novo in the site's review. Neither check changes the pass, and neither is presented as proof that no such ties exist — only that none surfaced in the review. The screen result is a fact about October 2026 figures, not a ruling on the company or on any investor's situation, and rulings on personal circumstances belong with a qualified scholar. But as a filter, the result is unambiguous today: Novo is inside the investable universe on this site's methodology, and Wednesday's beat, the guidance raise, the deferred 2027 call, and the January price cut do not change that, just as Wednesday's share rise does not change it. Price never rescues a failed gate, and a price rise never breaks a passing one.

There is one screen point that Wednesday's report does touch, and it belongs in this section rather than being left for the framework. Novo pays a dividend, and its payout is a practical question for a holder in a way that a non-payer's is not. Through September 2026, Novo paid 51.9 billion kroner in dividends and repurchased 10.0 billion kroner of shares. A holder receiving those dividends should purify the non-compliant share — 0.41 percent of revenue on the current screen — which is a small amount in absolute terms but is still a real obligation, and the purification guide and the purification calculator exist for exactly that calculation. The dividend does not change the screen result, and the purification does not change the dividend. But a halal investor who holds Novo and never purifies is holding a passing company incompletely, and the quarter's strong cash flow makes that a live question rather than a theoretical one: more cash returned means more to purify, even at 0.41 percent.

How a halal investor should approach a beat like this

A beat that lifts a stock by its biggest daily gain since June triggers a specific set of instincts, and they are worth naming before acting on any of them. The first is to buy immediately, because the stock rose and rising stocks feel like confirmation. The second is to buy because the multiple is low — about 11.5 times estimated 2026 earnings — and low multiples feel like discounts. The third is to wait for February, because management deferred the 2027 guidance and waiting feels like prudence. None of the three is a framework. A framework is a set of questions, answered in order, before any order is placed — and for a beat like this one, the questions are different from the questions for a sell-off, because the risk is not that the company is broken. The risk is that the market has priced in a future the company itself would not forecast. Here is the one this site's methodology implies, applied to Novo.

First, run the screen before you run the trade, and accept what it says about today. Novo passes as of October 2026, on all three gates, by wide margins, with independent screens in agreement and no BDS listing. That is the starting point, and it is a genuinely permissive starting point: unlike the CVS breakup, where the screen closed the conversation before it began, the Novo screen opens it. But a pass is not a recommendation. It is a filter that says the company is eligible for further analysis, and the further analysis is where the January price cut belongs. A halal investor who buys on the pass alone is making the same error, in the opposite direction, as the investor who sells on a fail alone: treating a screening result as an investment decision, when it is only the first step of one.

Second, separate the quarter from the guidance, in writing, as this article has done: adjusted sales up 4 percent, adjusted operating profit up 27 percent, guidance raised for the third time this year — and, separately, no 2027 guidance at all, and a 50 percent price cut on the flagship product from January. A good quarter does not validate a deferred forecast, and a deferred forecast does not invalidate a good quarter. Both statements can be true at once, and a halal portfolio is built on holding both of them steady rather than letting one swallow the other. Third, write down the one unknown that matters and refuse to fill it in with a guess: how much volume growth, at 675 dollars a month, offsets a 50 percent price cut. There is no precedent for that number in this market, and any analysis that proceeds as if it knew the answer — including your own — is unreliable. The February full-year results are the document that will answer it, and the disciplined move is to wait for that document before forming a view on 2027, rather than trading on Wednesday's 4 to 6 percent move as if it were the answer.

Fourth, compare like with like, and use the screen to do it. Novo and Lilly both pass, which means the choice between them is a choice between two eligible companies on different strengths — Lilly on growth, Novo on valuation and screen margin — and the right comparison is not Novo against the market, but Novo against the other passing names in the same sector. The screener hub lists every screened company, and the Novo screener page carries the full figures. Fifth, remember what this article is not. It is not a fatwa, and it is not a buy or sell call on Novo or on any other company. The screen result is a fact about October 2026 figures. The earnings numbers are facts about one quarter. The price cut is a fact about a January decision whose consequences are unpublished. Whether Novo belongs in your portfolio, at what size, and in which account, depends on your circumstances, your scholars' guidance, and advice suited to your situation. The framework above is designed to make that decision slower, written down, and checkable — the opposite of a day-one impulse on the biggest daily gain since June.

Finally, a note on the Canadian angle, because it is easy to overstate. Novo's primary listing is Nasdaq Copenhagen, and its shares trade in New York as American depositary receipts — which is how most Canadian investors would hold it, through a Canadian brokerage, in a registered or non-registered account. The Canadian relevance is practical rather than dramatic: the dividend arrives in kroner-converted dollars and is subject to Danish withholding tax, with the treaty rate and the Canadian foreign tax credit doing the work that a domestic dividend does not need; the price cut and the pill rollout are American market events that will show up in the ADR price; and the purification calculation runs on the same 0.41 percent ratio regardless of the account. None of that changes the screen, and none of it is a reason to favour or avoid the name. It is simply the plumbing of holding a Danish company through a Canadian account, and the plumbing should be checked before the position is sized, not after.

What to watch next

The next document that matters is not an earnings report. It is the full-year 2026 results in February 2027, when the company has promised to give the 2027 forecast it declined to give on Wednesday. Watch for three numbers in that release, in this order. First, the 2027 guidance itself: what range does the company put on sales and operating profit, and does that range imply that the pill's volume growth at 675 dollars a month offsets the 50 percent Wegovy price cut, or does it imply a year of decline? That single range will tell you more about the next twelve months than Wednesday's entire quarter. Second, the pill's trajectory in the first weeks of January: does the volume growth that carried the third quarter survive the price cut, or was some of it pulled forward by access programmes that will not repeat at the new price? Third, the CagriSema decision: does the United States launch go ahead early in 2027, and does the 12.4 percent weight-loss result translate into a product that can compete with Lilly's tirzepatide on its own terms?

Closer in time, watch the rest of this week's calendar, because Novo's beat lands in a week with more tests coming. The October jobs report arrives Friday 6 November at 8:30 a.m. Eastern, and it will set the tone for the market Novo trades in. Airbnb and Cloudflare report after the close on Thursday 5 November, and Qualcomm — which reported after the close on Wednesday with earnings of 2.17 dollars per share against 2.16 expected and revenue of 10.32 billion dollars against 10.12 billion expected — will show whether the chip rally that lifted the market on Wednesday has legs. McDonald's also reported on Thursday morning, with earnings of 3.57 dollars per share against 3.38 expected but revenue of 7.16 billion dollars against 7.28 billion expected — a beat on profit and a miss on sales, the mirror image of Novo's quarter in miniature, and a reminder that this season's pattern is not one story but many. Also watch for any update on the pill's rollout beyond the United States: the plan to reach more than 20 countries by mid-2027 is the international leg of the growth story, and international GLP-1 sales grew 8 percent in the quarter against 1 percent in the United States, which is where the company's own guidance says the growth will come from.

For readers who hold Novo, the practical next step is unglamorous and that is the point: note the screen result as it stands, note the one unknown — the 2027 arithmetic at 675 dollars a month — and wait for February before forming any view on next year. For readers who do not hold it, the next step is the same screen-first habit applied to whatever you do hold — because the next earnings beat will not be Novo, and the framework that worked this morning is the one that will work then. Run it through the screening methodology, check the company on the Novo screener page, compare it with the passing names on the screener hub, and build the rest of the decision from there. Earnings season rewards the investor who reads the guidance behind the headline. Wednesday was the latest proof — a beat, a raised outlook, and a forecast that management would not give, all in one announcement, and only the forecast they withheld is the one that will decide 2027. For the full list of this season's stories, see the market news hub.

FAQ

What did Novo Nordisk report for the third quarter of 2026?

Novo Nordisk reported adjusted sales of 79.20 billion Danish kroner, up 4 percent at constant exchange rates and ahead of the 73.22 billion analysts expected, and adjusted operating profit of 31.72 billion kroner, up 27 percent at constant exchange rates and ahead of the 28.39 billion expected. Adjusted earnings per share were 5.79 kroner against 4.80 expected. Reported operating profit fell 9 percent to 23.01 billion kroner after 8.7 billion kroner in non-cash impairment charges, and net profit fell 16 percent to 16.74 billion kroner.

Why did the shares rise if profit fell?

The shares rose as much as 6.6 percent in early Copenhagen trade and were up 4.2 percent at 1318 GMT, headed for their biggest daily gain since 19 June, because the market was pricing the adjusted beat and the third guidance raise of the year, not the reported profit. Novo raised its full-year 2026 outlook to between a 2 percent decline and 2 percent growth for both adjusted sales and adjusted operating profit, up from a 6 percent decline to flat, after starting the year expecting a 5 to 13 percent decline.

What is the Wegovy pill, and why does it matter?

The Wegovy pill is a daily oral version of Novo's weight-loss drug, launched in the United States on 5 January 2026. It brought in 5.39 billion Danish kroner in the third quarter, up 53 percent on the second quarter and ahead of the 4.62 billion consensus, and holds about 80 percent of new-to-brand prescriptions in the United States. About 80 percent of patients who started on the pill had previously been untreated, so the pill is expanding the treated population rather than mostly converting existing injection patients.

What happens to Wegovy and Ozempic prices in January 2027?

From 1 January 2027, Novo will cut United States list prices for Wegovy by about 50 percent and for Ozempic by about 35 percent, bringing both to 675 dollars a month. The company expects the cuts to weigh on cash flow next year, and chief executive Mike Doustdar declined to give 2027 guidance, deferring that call to the full-year results in February 2027.

Does Novo Nordisk still pass the Shariah screen?

Yes. Novo still passes this site's October 2026 Shariah screen on all three gates. The business is prescription pharmaceuticals with no haram segments disclosed. Interest-bearing debt of 130,958 million Danish kroner is about 12.0 percent of a market capitalisation of about 171 billion dollars, below the roughly 33 percent ceiling. Interest income of 1,269 million kroner is about 0.41 percent of revenue of 309,064 million kroner, below the 5 percent ceiling. Zoya rates Novo Shariah-compliant and Musaffa classifies it halal, both as of October 2026, and no BDS listing was found.

Is anything in this article a fatwa or a buy or sell call?

No. Everything here is facts and screening methodology only, with no fatwas and no personalised buy or sell calls. Rulings on your own situation belong with a qualified scholar, and investment decisions belong with advice suited to your circumstances. Not financial advice. Facts and screening methodology only, no fatwas.

Affiliate disclosure. This page contains no affiliate links, and the site currently earns no affiliate revenue. If we join affiliate programs in the future, this disclosure will be updated and links will be clearly labeled. Commissions never influence our scores or rankings — this review is based on official documentation and public data, and every product is Shariah-screened before review. Nothing on this site is financial advice.